Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7478-7488
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7478
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7478
Figure 7 Pathway of VEGFR-2 (produced using the Pathway Builder Tool).
Bevacizumab targets VEGF-A to prevent its interaction with VEGFR-2; apatinib mainly targets VEGFR-2. VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor.
- Citation: Li CM, Liu ZC, Bao YT, Sun XD, Wang LL. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World J Gastroenterol 2017; 23(41): 7478-7488
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7478.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7478